II. Epidemiology
- More than 20 million Sexually Transmitted Infections in the U.S. per year (as of 2022)
- Human Papillomavirus (HPV) is the most common U.S. Sexually Transmitted Infection (and preventable with the HPV Vaccine)
- Trichomonas vaginalis is the most common non-viral U.S. Sexually Transmitted Infection
- Chlamydia trachomatis and Mycoplasma Genitalium are the first and second most common U.S. Sexually Transmitted Infection
III. Risk Factors: High Risk Groups for STD
- Adolescents and young adults (ages 15 to 24 years old)
- Multiple partners
- Sequential monogamy
- Unconcerned
- Uniformity
- Inconsistent Condom use
- Racial or ethnically skewed
- Black: Chlamydia more common
- Homosexual men (or Men who have Sex with Men)
- Transgender Person
- Coasts or Ports of entry
- Prostitutes
- Teenage runaways
- Immigrants
- Low income in urban setting
- Prison Inmate (current or former)
- Military recruits
- Mental Illness
- Injection drug user (IV Drug Abuse)
- Sexual Abuse history
- Sexually Transmitted Infection history
IV. Pathophysiology: Transmission
- Contact
- Secretions
- Mucus membrane
- Skin Abrasion
- Intercourse not necessary for STD transmission
V. Causes
- Sexually Transmitted Disease Genital Ulcers
- See Genital Ulcers (Mnemonic: CHISEL)
- E in CHISEL is Drug Eruption
- Painful Ulcers
- Chancroid
- Herpes Genitalis
- Trichomonas may also cause labial ulcerations
- Non-Painful Ulcers
- See Genital Ulcers (Mnemonic: CHISEL)
- Sexually Transmitted Disease Non-ulcerative
- Bacterial
- See Non-Gonococcal Urethritis
- Pelvic Inflammatory Disease
- Gonorrhea
- Chlamydia
- Syphilis (Secondary or tertiary)
- Viral Infections
- Parasitic Infection
- Pediculosis Pubis
- Scabies (pruritic genital bumps awaken patient)
- Bacterial
- Emerging Sexually Transmitted Infections
- Monkeypox
- Hepatitis A Virus
- Mycoplasma Genitalium
- Zika Virus
- Lymphogranuloma venereum (LGV)
- Presents with Inguinal Lymphadenopathy or Proctitis
- Shigella flexneri
- Associated with anal sex and oro-anal sex, and presents with severe Diarrhea
- Multi-drug resistant and treatment requires susceptibility testing
- Associated with HIV Infection
- Neisseria Meningitidis
- Colonizes oropharynx of up to 10% of the U.S.
- Colonization of the Urethra, Cervix and Rectum has been found
- As of 2023, symptomatic localized infection responds to single dose Azithromycin or Ceftriaxone
- Cohorts of STI
- Urethritis in men who have sex with women
- Invasive meningococcal disease in Men who have Sex with Men
- Colonizes oropharynx of up to 10% of the U.S.
VI. Findings: Genitourinary Gonorrhea or Chlamydia (Male)
- Symptoms
- Dysuria
- Urinary Frequency
- Urethral meatus discharge
- Urethral Pruritus
- Painful ejaculation
- Signs
- Mucopurulent Urethral discharge
- Unilateral Testicular Pain
- Complications
VII. Findings: Genitourinary Gonorrhea or Chlamydia (Female)
- Symptoms
- Vaginal Discharge
- Postcoital spotting
- Dyspareunia
- Signs
- Genital Ulcers
- Cervicitis
- Erythema of Cervix
- Mucopurulent discharge from Cervical os
- Complications
- Pelvic Inflammatory Disease
- Fever, uterine and Adnexal tenderness, cervical motion tenderness, Vaginal Discharge
- Perihepatitis (Fitz-Hugh-Curtis Syndrome)
- Pelvic Pain and right upper quadrant pain with fever, Vomiting and abnormal LFTs
- Pelvic Inflammatory Disease
VIII. Findings: Extra-Genital Gonorrhea or Chlamydia
- Oropharyngeal Findings
- Pharyngitis
- Oropharyngeal exudate
- Cervical Lymphadenitis
- Anorectal Findings (also caused by syphillis, HSV, in addition to GC and Chlamydia)
- Anal Pruritus
- Rectal Pain
- Pain with anorectal intercourse
- Rectal Bleeding
- Rectal discharge
- Tenesmus
- Reactive Arthritis (Reiter's Syndrome)
-
Lymphogranuloma venereum (Chlamydia)
- Unilateral, swollen and tender inguinal or femoral Lymph Nodes
- Ulcer or Papule overlying Lymph Nodes may be present
- Fever
- Rectal symptoms
- Rectal Bleeding
- Rectal mucoid discharge
- Rectal Pain
- Tenesmus
- Constipation
-
Disseminated Gonococcal Infection
- Migratory polyarthritis (asymmetric, Pauciarticular)
- Tenosynovitis
- Fever
- Dermatitis (distal extremity necrotic lesions)
- May be complicated by endocarditis or Meningitis
IX. Precautions
- Only 30% of Sexually Transmitted Infections are symptomatic
-
Dysuria is not synonymous with Urinary Tract Infection (UTI)
- Consider Sexually Transmitted Infection (STI) in sexually active women presenting with Dysuria
- Urine White Blood Cells and positive Leukocyte esterase are seen in both UTIs as well as STIs
- Extra-genital sites of Gonorrhea and Chlamydia infection are often missed
- Ask a Sexual History including practices, and screen oropharynx and Rectum as indicated
- Urine-Only screening may miss Sexually Transmitted Infection in >80% of patients
- Pharyngeal Gonorrhea in Men who have Sex with Men
- Pharyngeal and Rectal Gonorrhea, and Rectal Chlamydia in women who have sex with men
- Pregnancy-related Sexually Transmitted Infection
- See Chorioamnionitis
- See Postpartum Endometritis
- See TORCH Infection
- STI in pregnancy is high risk for complications (e.g. IUGR, PROM, Stillbirth, preterm birth, neonatal infection)
- Universal screening in all pregnant women under age 25 years at first Prenatal Visit (and often in all women)
- Rescreen pregnant women in 4 weeks after completing STI treatment, and again in 3 months, and third trimester
- Neonatal and Perinatal Sexually Transmitted Infection
- See Perinatal HIV Transmission
- See Neonatal Herpes Simplex Virus
- See Perinatal Hepatitis B Exposure
- See Congenital Syphilis
- Gonorrhea
- Perinatal Gonorrhea infection affects up to 0.4 cases in 100,000 U.S. live births
- Risk of gonococcal Ophthalmia Neonatorum (risk of newborn blindness if prophylaxis is not used)
- Risk of Disseminated Gonorrhea infection in newborns (e.g. Septic Arthritis, Meningitis, Pneumonia)
- Chlamydia
- Risk of chlamydia Ophthalmia Neonatorum (later presentation than with Gonorrhea)
- Risk of Neonatal Chlamydia Pneumonia
X. Labs: Screening First-Line
- Genitourinary Gonorrhea and Chlamydia Testing
- Tests
- Chlamydia DNA Probe
- Gonorrhea DNA probe
- Sources
- Tests
- Extragenital Testing (pharynx, Rectum) for Gonorrhea and Chlamydia
- Several DNA and NAAT are approved for extragenital testing (e.g. Aptima Combo 2, Xpert CT/NG)
- Point-of-care tests are available for Gonorrhea and Chlamydia genitourinary and extra-genital testing
- Binx IO Point-Of-Care Test for female cervical swabs and male urine tests
- High accuracy with results in 30 minutes
- Clebak (2022) Am Fam Physician 106(5): 575-7 [PubMed]
- Binx IO Point-Of-Care Test for female cervical swabs and male urine tests
- Vaginal Exam
- Trichomonas DNA probe
- Replaces Wet Prep which only has a 50 to 65% Test Sensitivity for Trichomonas
- Vaginal Wet Prep
- Positive: Polymorphonuclear Leukocytes (PMNs) >10/hpf
- Efficacy
- Test Sensitivity: 90%
- Test Specificity: 87%
- Reference
- Trichomonas DNA probe
- Broad STI Screening in those at risk, including those testing positive for Gonorrhea and Chlamydia
- HIV Test
- Syphilis (RPR)
- Hepatitis B Testing (if not immunized)
- Other Testing to consider
- Consider Urinalysis
- Consider Urine Pregnancy Test
XI. Differential Diagnosis
- Conjunctivitis
-
Urethritis
- See Urethritis
- See Urethritis in Women
- See Urethritis in Men
- See Epididymitis
- See Acute Prostatitis
-
Vaginitis
- See Vaginitis
- See Acute Cervicitis
- See Pelvic Inflammatory Disease
- Other Findings
XII. Management
- Emergency department empiric treatment
- Initiating empiric treatment for suspected STD prior to results (often delayed days) is appropriate
- Despite risk of overtreatment, treat for suspected Chlamydia and Gonorrhea (prevents spread, complications)
- Gonorrhea management
- Ceftriaxone 500 mg IM/IV for 1 dose (1 gram IM/IV if weight > 150 kg, dose increased in 2020) OR
- Gentamicin 240 mg IM and Azithromycin 2 g orally for one dose OR
- Cefixime 800 mg orally once is an alternative but NOT recommended due to Antibiotic Resistance
- Chlamydia management if not excluded (not indicated for Gonorrhea treatment without Chlamydia as of 2020)
- Doxycycline 100 mg twice daily for 7 days (preferred as of 2020) OR
- Azithromycin 1 g orally for 1 dose
- References
- Gonorrhea management
- Avoid sexual contact until Antibiotic course is completed
- Rescreening
- Routinely Rescreen positive STD cases in 3 months to identify new STD infections
- Rescreen pregnant women in 4 weeks after completing treatment, and again in 3 months, and in third trimester
- Only other indicated early rescrening at 7 to 14 days (screening for cure) is for pharyngeal Gonorrhea
- Peterman (2006) Ann Intern Med 145:654-72 [PubMed]
- Clinic Visits
- Symptomatic patients should have in-person clinical examinations
- Consider Telemedicine for Sexually Transmitted Infection screening in asymptomatic patients
- At-home Chlamydia trachomatis and NeisseriaGonorrhea tests are available (not FDA approved)
- Medical provider or nurse instructed sample self-collection can be instructed on Telemedicine
- At home Test Sensitivity may be lower, but allows for screening more patients with fewer barriers
- Canevale (2021) Sex Transm Dis 48(1): e11-4 [PubMed]
- Fajardo-Bernal (2015) Cochrane Database Syst Rev (9):CD011317 [PubMed]
- Kersh (2021) J Clin Microbiol 59(11): e0264620 [PubMed]
XIII. Management: Expedited Partner Treatment
- Empiric STI treatment for an asymptomatic sexual partner of a patient being seen for STI
- Precaution: Legality of Expedited Partner Treatment varies by State in the United States
- http://www.cdc.gov/std/ept/legal/
- As of 2022, permitted in 46-49 states (not legal in South Carolina)
- Patients may anonymously notify their partner
- Ideally sexual partners are seen for their own medical evaluations
- However, delaying their treatment until evaluation risks re-exposing treated patients
- CDC asks physicians to consider treating sexual partners of STD patients without a visit
- Employ in cases where sexual partner is unlikely to present for medical care
- Prescription for sexual partner's STD treatment is given to the patient being treated
- Some states may allow prescription labeled for "EPT" or "partner"
- Do not double up on prescription quantity for one patient (write 2 separate prescriptions)
- Example protocol for partner (prescriptions given to patient to bring to partner)
- Provider should ask about partner's medication allergies, other medications and pregnancy
- Written instructions should be given to the patient to convey to their sexual partner
- Patient and their partner should abstain from sex until both have completed Antibiotic course
- Regimen
- Cefixime 800 mg (if partner will be seen, Ceftriaxone 500 mg IM/IV is preferred) AND
- Azithromycin 1 gram orally (or preferred option is Doxycycline 100 mg twice daily for 7 days)
- References
XIV. Prevention: Including Post-exposure Prophylaxis
- Consistent Condom Use
- Vaccination
- STI Postexposure Prophylaxis
- See Sexual Assault
- See Doxy PEP below
- HIV Postexposure Prophylaxis
- Other measures
- HIV Preexposure Prophylaxis (HIV PrEP)
- Expedited Partner Treatment (see above)
XV. Prevention: Doxycycline Post-Exposure Prophylaxis (Doxy PEP)
- Encourage safe sex practices (e.g. Condoms, and other PEP/PREP)
- Indications
- Bacterial STI in the last year (Syphilis, Gonorrhea, Chlamydia) AND
- Specific high risk patients
- Men who have Sex with Men (MSM)
- Transgender women (TGW)
- Protocol
- See Doxycycline for precautions (take with 8 oz fluid, avoid with Antacids, use Sunscreen)
- Patient takes 200 mg Doxycycline as soon as possible after sex (oral, vaginal, anal) and within 72 hours
- Limit to one dose in 24 hours
- Efficacy
- NNT 3 to prevent one Bacterial STI per year
- References
- Stewart (2022) Trials 23(1):495 +PMID: 35710444 [PubMed]
- Luetkemeyer (2022) AIDS 2022 Conference Abstract
XVI. Prevention: Screening Asymptomatic Patients (USPTF guidelines)
- See Risk Factors listed above
- Behavioral counseling (proper Condom use, safe sex, difficult sexual situations)
- All sexually active adolescents
- Adults at risk for Sexually Transmitted Infection
- Emphasize barrier protection (e.g. Condoms) as best method to prevent Sexually Transmitted Infection during sex
-
Gonorrhea and Chlamydia screening
- All sexually active adolescents 24 years old and younger every year (and repeated 3 months after positive testing)
- Women at risk for Sexually Transmitted Infection
- Pregnancy age <= 24 years or any age if high risk (at first visit, and if risk then repeat in third trimester)
- Men who have Sex with Men (consider rectal and pharyngeal screening as well)
- Correctional facilities at intake (men age <30 years, women age <35 years)
-
HIV Screening
- All patients ages 15 years old to 65 years old (or if risks)
- All pregnant women at first Prenatal Visit (or at time of delayed presentation)
-
Hepatitis B
Virus Screening
- All pregnant women at first Prenatal Visit (or at time of delayed presentation)
- Patients at risk of infection
- Immigrants from sub-sahara Africa, Central and Southeast Asia, China (esp. unimmunized)
- Household HBV Contacts
-
Syphilis Screening
- All pregnant women at first Prenatal Visit (or at time of delayed presentation)
- Patients at risk of infection
- Herpes Simplex Virus Infection Screening
- References
XVII. Resources: Patients
- CDC National STD Hotline (CDC)
- http://www.cdc.gov/std/
- Phone: 800-232-4636
- Expedited Partner Treatment (CDC)
- Information from your Family Doctor: Prevent AIDS
- Inspot.Org (annonymously notify others of STD exposure)
- DontSpreadIt.Com (annonymously notify others of STD exposure)